Dernières nouvelles pour Corvus Pharma (NASDAQ:CRVS) Stock

CORVUS PHARMACEUTICALS INC

Corvus Pharma

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in&nbsp;China,&nbsp;Angel Pharmaceuticals Ltd.&nbsp;(Angel Pharma), has been approved by the&nbsp;Center for Drug Evaluation&nbsp;(CDE) of the&nbsp;China National Medical Products Administration&nbsp;(NMPA) to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in&nbsp;China.
Corvus co-founded Angel Pharma to develop its pipeline in greater&nbsp;China.&nbsp;Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize soquelitinib in greater&nbsp;China and is responsible for all expenses related to its development in&nbsp;China.
Angel Pharma's Phase 1b/2 clinical trial for soquelitinib in patients with atopic dermatitis will build on the data previously presented by Corvus from its ongoing Phase 1 trial by studying a longer treatment period and an additional dosing option. The Phase 1b trial will be randomized, double-blinded, placebo-controlled and enroll patients with moderate-to-severe atopic dermatitis as follows:
<ul>
<li>Soquelitinib Cohort 1 (24 patients) – 8 patients receive placebo, 8 patients receive soquelitinib 100 mg twice per day and 8 patients receive soquelitinib 200 mg once per day</li>
<li>Soquelitinib Cohort 2 (24 patients) – 8 patients receive placebo, 8 patients receive soquelitinib 200 mg twice per day and 8 patients receive soquelitinib 400 mg once per day</li>
<li>The treatment period will be 12 weeks</li>
</ul>
The Phase 2 trial will also be a randomized, double-blinded, placebo-controlled study. It will enroll additional patients and focus on two doses that will be selected based on the safety and efficacy results from the Phase 1b trial.
The principal investigator of the Phase 1b/2 clinical trial is Yuling Shi, M.D, Ph.D. Dr. Shi is professor of dermatology, the Vice President of Shanghai Skin Disease Hospital at the Tongji University School of Medicine, and the founder and director of the Institute of Psoriasis at Tongji University School of Medicine, the first psoriasis institute in China. Dr. Shi has published more than 100 peer-reviewed articles, most focusing on psoriasis, skin autoimmunity, and inflammatory skin diseases.

News

CRVS

Corvus Says Partner Angel Pharma's IND Approved By CDE Of China NMPA To Initiate Phase 1b/2 Clinical Trial Of Soquelitinib For Treatment Atopic Dermatitis In China

Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is taking place June 11-14, 2025 in Barcelona. The poster will be presented by Gonçalo Boleto, M.D., MSc, a rheumatologist at Centro Académico de Medicina de Lisboa, Portugal. It was selected as a top 10 abstract by the Emerging EULAR Network (EMEUNET), a network of young rheumatologists and researchers in the field of rheumatology in Europe and beyond.

Corvus Pharma To Present Preclinical Data Highlighting Potential Of Soquelitinib To Treat Systemic Sclerosis At EULAR 2025 Congress

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2
All three cohorts show separation from placebo with statistically significant difference from placebo at day 28
Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8
Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data includes 28-day follow up results for all patients in cohort 3 and continues to show earlier and deeper responses in cohort 3 (200 mg twice per day, total daily dose 400 mg) compared to cohorts 1 and 2 (100 mg twice per day and 200 mg once per day, total daily dose 200 mg). Overall, data from cohorts 1-3 of the trial have demonstrated a favorable safety and efficacy profile, including a statistically significant improvement in Eczema Area and Severity Index (EASI) score for the soquelitinib treated patients compared to placebo at day 28 (p=0.036).

Corvus Pharma Announces New Interim Data From Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial Evaluating Soquelitinib In Patients With Moderate To Severe Atopic Dermatitis

Mizuho analyst Graig Suvannavejh maintains Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Outperform and lowers the price target from $12 to $11.

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Corvus Pharma, Lowers Price Target to $11

WIIM

Corvus Pharmaceuticals shares are trading higher after it reported Q1 EPS. Company also reported data from its Cohorts 1-3 of Placebo-Controlled phase 1 clinical trial.

Oppenheimer analyst Jeff Jones reiterates Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Outperform and raises the price target from $15 to $17.

Reiteration

Oppenheimer Reiterates Outperform on Corvus Pharma, Raises Price Target to $17

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 43.9% to $305.0 during Friday's regular session. The company's market cap stands at $3.9 billion. </li>
<li>Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) shares rose 39.29% to $3.19. The company's market cap stands at $222.1 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares rose 38.75% to $0.76. The market value of their outstanding shares is at $1.7 million. </li>
<li>Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) shares increased by 32.74% to $3.73. The market value of their outstanding shares is at $402.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares increased by 29.85% to $4.35. The market value of their outstanding shares is at $296.5 million. The company's, Q1 earnings came out yesterday. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares rose 28.37% to $0.01. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock fell 53.8% to $0.05 during Friday's regular session. </li>
<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock declined by 43.85% to $1.78. The company's market cap stands at $594.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Organogenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) stock decreased by 43.36% to $3.02. The market value of their outstanding shares is at $383.7 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock decreased by 43.09% to $3.5. The company's market cap stands at $1.8 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) shares decreased by 37.46% to $4.87. The company's market cap stands at $126.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 35.85% to $0.38. The market value of their outstanding shares is at $2.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CVRX

IOVA

LGMK

NCNA

NDRA

ORGO

PHAT

PLRZ

WORX

12 Health Care Stocks Moving In Friday's Intraday Session

Corvus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) on Thursday released new interim data from the Phase 1 clinical trial evaluating soquelitinib in patients with moderate to <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">severe atopic dermatitis</a>.
The data demonstrated a favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 (200 mg twice per day, total daily dose 400 mg) compared to cohorts 1 and 2 (100 mg twice per day and 200 mg once per day, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45298954/corvus-pharmaceuticals-announces-data-from-cohorts-1-3-of-placebo-controlled-phase-1-clinical-tria" rel="noreferrer noopener">total daily dose 200 mg)</a>.
Overall, all three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints of EASI&nbsp;(Eczema Area and Severity Index) 75 and IGA (Investigator Global Assessment) 0 or 1.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42560659/why-is-corvus-pharmaceuticals-stock-trading-lower-on-wednesday" rel="noreferrer noopener">Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?</a>
The percent reduction in mean EASI scores at 28 days for the combined cohort 1 and 2 group was 54.6% for patients receiving soquelitinib and 30.6% for patients receiving placebo.
In cohort 3, the percent reduction in mean EASI score at 28 days was 71.1% for patients receiving soquelitinib and 42.1% for patients receiving placebo.
Separation of the curves for patients receiving active drug began at day 15 and increased by day 28 for cohorts 1 and 2.
Cohort 3 patients experienced earlier and deeper separation from placebo starting by day 8. The combined soquelitinib treatment group is significantly superior to placebo at day 28, p=0.03.
Soquelitinib was well tolerated, with no dose-limiting toxicities (DLTs) and no clinically significant laboratory abnormalities observed in any of the cohorts.
No interruption of drug dosing was seen in any of the cohorts. Grade 1/2 adverse events (treatment-related and unrelated) were seen in 33.3% of patients receiving soquelitinib and 25% receiving placebo.
Only one treatment-related adverse event of grade 1 nausea was reported with soquelitinib treatment.
As reported, relationships between reductions in certain cytokines and improvement in EASI scores were observed.
<ul class="wp-block-list">
<li>Differences between responding and non-responding patients were found, while no such relationships were seen in the placebo group.</li>
</ul>
The number of circulating T regulatory cells increased, consistent with the presumed mechanism of action of soquelitinib.
"We continue to be encouraged by the results from our phase 1 trial of soquelitinib in patients with atopic dermatitis, which show a favorable safety and efficacy profile with a convenient oral tablet. We believe the results are particularly exciting given the relatively short treatment duration of 28 days and durable post-treatment results, both of which we associate with the novel mechanism of action provided by ITK inhibition," said Richard Miller, co-founder, president, and CEO.
"Looking forward, we remain on track with our key potential value-driving initiatives for soquelitinib in atopic dermatitis, including data from our new extension cohort in the fourth quarter and initiating a Phase 2 clinical trial before year-end. We also remain excited about our other soquelitinib clinical programs – patient enrollment in the Phase 3 registration clinical trial in peripheral T cell lymphoma (PTCL) and the Phase 2 trial in autoimmune lymphoproliferative syndrome (ALPS) is ongoing, and we plan to initiate a solid tumor clinical trial later in 2025," <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45299055/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">Miller added</a>.
As of March 31, 2025, Corvus had cash, cash equivalents and marketable securities of $44.2&nbsp;million. Based on its current plans, Corvus expects its cash to fund operations into the fourth quarter of 2026.
Price Action: CRVS stock is up 28.40% at $4.30 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45316190/phx-minerals-stock-soars-after-securing-21-8-premium-in-acquisition-deal" target="_blank" rel="noreferrer noopener">PHX Minerals Stock Soars After Securing 21.8% Premium In Acquisition Deal</a></li>
</ul>

Biotech

Health Care

Trading Ideas

General

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

<h3>Gainers</h3>
<ul>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock increased by 79.5% to $0.48 during Friday's pre-market session. The company's market cap stands at $3.0 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock increased by 51.0% to $0.83. The market value of their outstanding shares is at $1.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock increased by 29.85% to $4.35. The company's market cap stands at $296.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares increased by 24.77% to $1.36. The company's market cap stands at $108.9 million. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) shares increased by 18.62% to $0.43. The company's market cap stands at $28.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) stock rose 16.82% to $0.56. The company's market cap stands at $46.2 million. The company's, Q1 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) shares decreased by 44.5% to $5.0 during Friday's pre-market session. The market value of their outstanding shares is at $263.0 million. </li>
<li>Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares declined by 42.2% to $5.0. The company's market cap stands at $206.1 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 41.5% to $0.06. </li>
<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock decreased by 35.02% to $2.06. The company's market cap stands at $687.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares declined by 30.93% to $0.41. The company's market cap stands at $2.7 million. </li>
<li>Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) stock fell 26.65% to $2.12. The market value of their outstanding shares is at $168.5 million. As per the news, the Q1 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACET

CTMX

GBIO

JBIO

SHPH

VREX

12 Health Care Stocks Moving In Friday's Pre-Market Session

Shares of Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter sales results and issued second-quarter sales guidance with its midpoint above estimates. Also, Pinterest&#8217;s reported an increase in its <a href="https://www.benzinga.com/general/social-media/25/05/45300764/pinterest-stock-surges-on-q1-earnings-company-sees-continued-momentum-in-revenue-user-growth-engagement">monthly average users</a>.
Pinterest reported first-quarter revenue of $855 million, beating estimates of $846.59 million, according to Benzinga Pro. The idea discovery platform company reported first-quarter adjusted earnings of 23 cents per share, missing analyst estimates of 26 cents per share.
Pinterest shares jumped 12.7% to $31.40 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>ZK International Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZKIN#NASDAQ">ZKIN</a>) rose 88.8% to $4.76 in pre-market trading after jumping 129% on Thursday.</li>
<li>SCWorx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) surged 75.1% to $0.9595 in pre-market trading.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) gained 37% to $4.59 in pre-market trading after it reported first-quarter EPS. The company also reported data from its Cohorts 1-3 of Placebo-Controlled phase 1 clinical trial.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) jumped 22.3% to $0.33 in pre-market trading after the company announced FDA orphan-drug nears patient enrollment milestone for phase 2 clinical trial.</li>
<li>PHX Minerals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) gained 20.8% to $4.33 in pre-market trading after WhiteHawk announced plans to but the company for $4.35 per share.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) surged 16.5% to $108.84 in pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates.</li>
<li>Green Dot Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) climbed 14.8% to $10.00 in pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance above estimates.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) gained 14.2% to $68.36 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>Clean Energy Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETY#NASDAQ">CETY</a>) gained 12.6% to $0.5293 in pre-market trading after rising 18% on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Jade Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) shares dipped 44.4% to $5.00 in pre-market trading.</li>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 39.2% to $0.0626 in pre-market trading after dipping 66% on Thursday. NuCana recently announced a registered direct offering with approximately $7 million gross proceeds.</li>
<li>Twin Vee Powercats Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) shares fell 38.7% to $4.57 in pre-market trading after the company announced the pricing of public offering.</li>
<li>Super League Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) fell 37.5% to $0.2033 in pre-market trading after the company announced the launch of a proposed public offering.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) shares tumbled 35.6% to $2.04 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Profound Medical Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) dipped 34.7% to $3.25 in pre-market trading after posting downbeat quarterly earnings.</li>
<li>Solidion Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) fell 25.6% to $0.1170 in today's pre-market trading. Solidion Technology shares jumped 67% on Thursday after the company presented its patented technology for transforming lithium-ion facilities into battery producers.</li>
<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) fell 17.2% to $60.00 in pre-market trading after the company reported worse-than-expected first-quarter financial results and cut its FY25 adjusted EPS guidance below estimates.</li>
<li>FIGS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) declined 16.2% to $4.22 in pre-market trading after reporting first-quarter results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) fell 13.2% to $3.84 in pre-market trading after reporting mixed quarterly results.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

CETY

FIGS

GDOT

GMED

PINS

PROF

TMDX

VEEE

WOLF

ZKIN

Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock moved upwards by 75.2% to $0.96 during Thursday's after-market session. The company's market cap stands at $2.2 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock rose 55.68% to $5.2. The company's market cap stands at $354.4 million. The company's, Q1 earnings came out today. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 25.81% to $0.34. The market value of their outstanding shares is at $2.1 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 19.55% to $2.14. The market value of their outstanding shares is at $51.9 million. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) stock rose 12.87% to $0.54. The company's market cap stands at $44.6 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares moved upwards by 12.62% to $104.97. The market value of their outstanding shares is at $3.5 billion. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock declined by 45.4% to $1.73 during Thursday's after-market session. The market value of their outstanding shares is at $577.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 44.42% to $0.06. </li>
<li>DocGo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) shares fell 20.61% to $1.85. The market value of their outstanding shares is at $183.3 million. As per the press release, Q1 earnings came out today. </li>
<li>AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) stock declined by 20.16% to $7.45. The company's market cap stands at $196.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Organogenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) stock declined by 18.54% to $4.35. The market value of their outstanding shares is at $551.8 million. The company's, Q1 earnings came out today. </li>
<li>Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) stock declined by 17.27% to $59.95. The market value of their outstanding shares is at $8.2 billion. As per the news, the Q1 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

DCGO

RCEL

12 Health Care Stocks Moving In Thursday's After-Market Session

Corvus Pharmaceuticals shares are trading higher after it reported Q1 EPS. Company also reported data from its Cohorts 1-3 of Placebo-Controlled phase 1 clinical trial

Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 8.33 percent decrease over losses of $(0.12) per share from the same period last year.

Earnings

Earnings Misses

Corvus Pharma Q1 EPS $(0.13) Misses $(0.12) Estimate

Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2
Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting

Corvus Pharmaceuticals Announces Data From Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib In Patients With Moderate To Severe Atopic Dermatitis

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CTEV

CTKB

CTLP

DAVE

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the&nbsp;Society for Investigative Dermatology (SID) 2025 Annual Meeting

Corvus Pharmaceuticals Announced New Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis

Corvus Pharmaceuticals shares are trading lower after the company reported Q4 financial results and missed its EPS estimate.

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Outperform and raises the price target from $14 to $15.

Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $15

HC Wainwright &amp; Co. analyst Sean Lee reiterates Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Buy and maintains $11 price target.

HC Wainwright & Co. Reiterates Buy on Corvus Pharma, Maintains $11 Price Target

Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.12) by 50 percent. This is a 28.57 percent decrease over losses of $(0.14) per share from the same period last year.

Corvus Pharma Q4 2024 GAAP EPS $(0.18) Misses $(0.12) Estimate

Press Releases

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Management

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

Comments

Corvus Pharma

Actualités

Dernières nouvelles pour Corvus Pharma (NASDAQ:CRVS) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL